News
BAYZF
43.80
NaN%
--
Bayer upgraded to Buy from Hold at DZ Bank
TipRanks · 18h ago
Bayer (0P6S) was upgraded to a Buy Rating at DZ BANK AG
TipRanks · 1d ago
Artiva Biotherapeutics names Diego Miralles president, head of R&D
PUBT · 1d ago
Bayer granted priority review for asundexian by FDA
TipRanks · 1d ago
Barclays Remains a Buy on Bayer (0P6S)
TipRanks · 1d ago
Bayer wins FDA priority review for asundexian to prevent secondary stroke
PUBT · 1d ago
BAYER AG - REGULATORY SUBMISSION IS BASED ON POSITIVE RESULTS FROM PHASE III OCEANIC-STROKE STUDY
Reuters · 1d ago
Goldman Sachs lifts Bayer voting rights to 5.34% from 4.44%
PUBT · 1d ago
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
Barchart · 2d ago
Bayer agrees to pay $133M for PCB cleanup in Michigan, Rhode Island
Seeking Alpha · 2d ago
Evogene unit AgPlenus, Bayer discontinue herbicide development project
PUBT · 2d ago
Bayer announces HYRNUO sNDA granted Priority Review status by FDA
TipRanks · 2d ago
U.S. FDA GRANTS PRIORITY REVIEW TO SUPPLEMENTAL NEW DRUG APPLICATION FOR HYRNUO® (SEVABERTINIB) UNDER INVESTIGATION AS A FIRST-LINE TREATMENT OF HER2-MUTATED NON-SMALL CELL LUNG CANCER
Reuters · 2d ago
BRIEF-Bayer - FDA Priority Review For Sevabertinib
Reuters · 2d ago
FDA grants Bayer sevabertinib priority review for first-line HER2-mutant lung cancer
PUBT · 2d ago
Leerink cuts Regeneron to Market Perform on LAG-3 failure, Eylea erosion risk
TipRanks · 2d ago
Weekly Report: what happened at BAYZF last week (0511-0515)?
Weekly Report · 2d ago
Bayer announces presentation of new Phase II ARASEC data on NUBEQA
TipRanks · 5d ago
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
Barchart · 5d ago
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
Barchart · 5d ago
More
Webull provides a variety of real-time BAYZF stock news. You can receive the latest news about Bayer A G through multiple platforms. This information may help you make smarter investment decisions.
About BAYZF
Bayer AG is a German-based life science company. The Company's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.